The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments
Chronic plaque psoriasis is an inflammatory skin disease affecting 2–3% of the general
population. Approximately one-third of patients are candidates for systemic …
population. Approximately one-third of patients are candidates for systemic …
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease …
Objective To update guidance regarding the management of psoriatic disease during the
COVID-19 pandemic. Study Design The task force (TF) includes 18 physician voting …
COVID-19 pandemic. Study Design The task force (TF) includes 18 physician voting …
Biologics for psoriasis during the COVID-19 pandemic
H Zeng, S Wang, L Chen, Z Shen - Frontiers in medicine, 2021 - frontiersin.org
Coronavirus disease 2019 (COVID-19), a new form of acute infectious respiratory syndrome
first reported in 2019, has rapidly spread worldwide and has been recognized as a …
first reported in 2019, has rapidly spread worldwide and has been recognized as a …
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies
MT Patrick, H Zhang, R Wasikowski, EP Prens… - Journal of Allergy and …, 2021 - Elsevier
Background Coronavirus disease 2019 (COVID-19) is commonly associated with skin
manifestations, and may also exacerbate existing skin diseases, yet the relationship …
manifestations, and may also exacerbate existing skin diseases, yet the relationship …
Tumor necrosis factor inhibitors are associated with a decreased risk of COVID‐19‐associated hospitalization in patients with psoriasis—A population‐based cohort …
The risk of coronavirus disease 2019 (COVID‐19) and its complications among patients with
psoriasis treated by tumor necrosis factor inhibitors (TNFis) remains to be decisively …
psoriasis treated by tumor necrosis factor inhibitors (TNFis) remains to be decisively …
Dupilumab therapy in atopic dermatitis is safe during COVID‐19 infection era: a systematic review and meta‐analysis of 1611 patients
AE El‐Qushayri, MA Mahmoud, S Salman… - Dermatologic …, 2022 - Wiley Online Library
The aim of this meta‐analysis is to evaluate the safety of dupilumab use in the management
of atopic dermatitis (AD) during the current pandemic regarding the risk and the hazards of …
of atopic dermatitis (AD) during the current pandemic regarding the risk and the hazards of …
SARS‐CoV‐2 (COVID‐19) vaccination in dermatology patients on immunomodulatory and biologic agents: recommendations from the Australasian medical …
C Wang, M Rademaker, B Tate… - Australasian Journal …, 2021 - Wiley Online Library
As the phase III COVID‐19 vaccine trials excluded patients on immunosuppressive
treatments, or patients with significant autoimmunity, the Australasian Medical Dermatology …
treatments, or patients with significant autoimmunity, the Australasian Medical Dermatology …
A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on …
Introduction This systematic review and meta‐analysis aims to investigate the mutual impact
of COVID‐19 and psoriasis to inform clinical practice and future research. Methods We …
of COVID‐19 and psoriasis to inform clinical practice and future research. Methods We …
The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey
Background Immunosuppressive therapy has been a great concern during the pandemic.
This study aimed to evaluate the pandemic's impact on psoriasis patients treated with …
This study aimed to evaluate the pandemic's impact on psoriasis patients treated with …
Psoriasis‐related treatment exposure and hospitalization or in‐hospital mortality due to COVID‐19 during the first and second wave of the pandemic: cohort study of 1 …
L Penso, R Dray‐Spira, A Weill… - British Journal of …, 2022 - academic.oup.com
Background Data on treatment exposures for psoriasis and poor COVID‐19 outcomes are
limited. Objectives To assess the risk of hospitalization or in‐hospital mortality due to COVID …
limited. Objectives To assess the risk of hospitalization or in‐hospital mortality due to COVID …